Voyager Therapeutics Inc.’s recently made public that its Chief Scientific Officer Carter Todd Alfred unloaded Company’s shares for reported $59400.0 on Jul 06. In the deal valued at $10.80 per share,5,500 shares were sold. As a result of this transaction, Carter Todd Alfred now holds 59,860 shares worth roughly $ 0.48 million.
Then, Sandrock Alfred sold 7,437 shares, generating $58,232 in total proceeds. Upon selling the shares at $7.83, the President and CEO now owns 214,618 shares.
Before that, Swartz Robin sold 1,259 shares. Voyager Therapeutics Inc. shares valued at $9,858 were divested by the Chief Operating Officer at a price of $7.83 per share. As a result of the transaction, Swartz Robin now holds 71,617 shares, worth roughly $0.57 million.
Truist initiated its Voyager Therapeutics Inc. [VYGR] rating to a Buy in a research note published on Friday, May 10, 2023; the price target was $18. PT values the company’s stock at a premium of 55.78 to its Friday closing price.
Price Performance Review of VYGR
On Friday, Voyager Therapeutics Inc. [NASDAQ:VYGR] saw its stock fall -3.05% to $7.96. On the same session, the stock had its day’s lowest price of $7.93, but rose to a high of $8.28. Over the last five days, the stock has lost -13.67%. Voyager Therapeutics Inc. shares have risen nearly 30.49% since the year began. Nevertheless, the stocks have risen 20.79% over the past one year. While a 52-week high of $14.34 was reached on 05/22/23, a 52-week low of $4.77 was recorded on 01/04/23. SMA at 50 days reached $9.29, while 200 days put it at $8.84. A total of 0.65 million shares were traded, compared to the trading of 0.26 million shares in the previous session.
Levels Of Support And Resistance For VYGR Stock
The 24-hour chart illustrates a support level at 7.83, which if violated will result in even more drops to 7.71. On the upside, there is a resistance level at 8.18. A further resistance level may holdings at 8.41. The Relative Strength Index (RSI) on the 14-day chart is 27.98, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.74%. Stochastics %K at 3.71% indicates the stock is a buying.
How much short interest is there in Voyager Therapeutics Inc.?
A steep rise in short interest was recorded in Voyager Therapeutics Inc. stocks on Aug 30, 2023, growing by 0.13 million shares to a total of 2.08 million shares. Yahoo Finance data shows the prior-month short interest on Jul 30, 2023 was 1.95 million shares. There was a rise of 6.25%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 5.93% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.59.
Voyager Therapeutics Inc. [VYGR] – Who Are The Largest Shareholders?
In filings from EcoR1 Capital, LLC, it is revealed that the company now owns 3,851,507 shares, or roughly 8.77% of the outstanding VYGR shares. Additionally, Armistice Capital LLC increased 2.84% of its stake after which the total value it holdings stand at $36,312,480, while The Vanguard Group, Inc. added 23.37% of its stake to hold $24.17 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 1,380,081 shares of Voyager Therapeutics Inc., while Farallon Capital Management LLC bought 495,000 shares. At present, T. Rowe Price Associates, Inc. is holding 1,205,741 shares valued at $12.08 million. D. E. Shaw & Co. LP owned 947,973 shares of the company at the time of its most recent 13F filing, worth $9.5 million.
According to FactSet, Voyager Therapeutics Inc.’s share price will average $12.57 in the next year, based on opinions of analysts polled by the firm. This is up nearly 70.52 percent from its previous closing price of $8.21. Analysts expect Voyager Therapeutics Inc. stock to reach the higher price of $18.00, while the lowest price estimate is $6.00. However, 8 analysts have rated VYGR stock as an Overweight in their predictions for 2023.